2018年泌尿生殖系统肿瘤研讨会（ASCO-GU）于2月8日在美国旧金山拉开帷幕。ASCO-GU研讨会由美国临床肿瘤学会（ASCO）、美国放射肿瘤学会（ASTRO）和美国泌尿肿瘤学会（SUO）共同主办。在为期三天的会议中，将展开多场泌尿系、男生殖系肿瘤的继续教育讲座，公布和讨论本系统肿瘤外科治疗、内科药物治疗、放疗、影像诊断、病理检查以及肿瘤生物预测评估等相关研究成果。现将泌尿系统肿瘤中治疗相关重要研究的大会摘要总结如下。
图片来源：ASCO官网
1.尿路上皮癌
化疗
NRGRTOG 0712-A 研究：对比肌层浸润性膀胱癌患者每日两次放疗+5-氟尿嘧啶顺铂（FCT）化疗和每日一次放疗+吉西他滨化疗的治疗效果
[Abstract 408] Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial
2月9日，周五， 10:45 AM-12:15 PM
General Session 5: Multimodality Approach to Locally Advanced Bladder Cancer (ARS)
围术期化疗辅助治疗上尿路上皮癌（UTUC）
[Abstract 407] Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)
2月9日，周五，7:55 AM-9:30 AM
Session 4：Current and Future Directions of Muscle-Invasive Bladder Cancer
肿瘤免疫治疗
CheckMate 032：Nivolumab单药治疗转移性尿路上皮癌
[Abstract 414] Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study
2月9日，周五，6:00 PM-7:00 PM
Rapid-Fire Abstract Session: Urothelial Carcinoma
KEYNOTE-045：派姆单抗（pembro）二线治疗复发进展性尿路上皮癌
[Abstract 410]wo-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel， docetaxel， or vinflunine) in recurrent， advanced urothelial cancer (UC)
2月9日，周五，1:45 PM-3:15 PM
Oral Abstract Session B: Urothelial Carcinoma and Penile， Urethral， and Testicular Cancers
2.前列腺癌
PROSPER研究：恩杂鲁胺（ENZA）治疗无远处转移的去势抵抗性前列腺癌
[Abstract 3] PROSPER: A phase 3， randomized， double-blind， placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC)
2月8日，周五，1:00 PM-2:30 PM
Oral Abstract Session A: Prostate Cancer
SPARTAN研究：apalutamide (APA)治疗无远处转移的去势抵抗性前列腺癌
[Abstract 161]SPARTAN， a phase 3 double-blind， randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
2月8日，周五，1:00 PM-2:30 PM
Oral Abstract Session A: Prostate Cancer
3.肾癌
外科治疗
IMDC数据：转移性乳头状肾细胞癌患者行减瘤性肾切除术
[Abstract 581] Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
2月10日，周六，1:00 PM-2:30 PM
Oral Abstract Session C: Renal Cell Cancer
生物靶向治疗
CABOSUN研究：卡博替尼对比舒尼替尼治疗晚期肾细胞癌
[Abstract 582]Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.
2月10日，周六，11:45 AM-12:45 PM
Rapid-Fire Abstract Session: Renal Cell Cancer
EORTC 90101 CREATE：克唑替尼在晚期乳头状肾细胞癌1型伴MET突变或扩增患者中的治疗
[Abstract 580] Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification Final results of EORTC 90101 CREATE
2月10日，周六，1:00 PM-2:30 PM
Oral Abstract Session C: Renal Cell Cancer
TemPa研究：对比帕唑帕尼和西罗莫司对晚期肾透明细胞癌的治疗研究
[Abstract 582] A randomized phase II trial of pazopanib (PAZ) versus temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (aCCRCC) of intermediate and poor-risk (the TemPa trial)
2月10日，周六
Rapid-Fire Abstract Session: Renal Cell Cance
肿瘤免疫治疗
IMmotion151 ：Atezolizumab+贝伐珠单抗对比舒尼替尼对初治转移性肾细胞癌中的效果
[Abstract 578]IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
2月10日，周六，1:00 PM-2:30 PM
Oral Abstract Session C: Renal Cell Cancer
NIVOREN GETUG-AFU 26研究：Nivolumab用于治疗转移性肾细胞癌的的安全性和有效性
[Abstract 577]
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study
2月10日，周六，2:45 PM-4:15 PM
General Session 9: Multidisciplinary Care of the Patient With Advanced Renal Cell Carcinoma
[Abstract 579] Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).
2月10日，周六，1:00 PM-2:30 PM
Oral Abstract Session C: Renal Cell Cancer
京公网安备 11010502033352号